Differential antagonistic effects of finerenone and spironolactone on the aldosterone transcriptome in human kidney cells.
Aldosterone, the main mineralocorticoid hormone in humans, controls, via gene transregulation, various renal functions including water and sodium reabsorption and potassium excretion. Dysregulations in the aldosterone signaling pathway lead to renal dysfunctions, including chronic kidney disease and renal fibrosis, that can be prevented or treated with mineralocorticoid receptor antagonists (MRAs). To understand the global effects of aldosterone on the human renal transcriptome, and how it is antagonized by the MRAs spironolactone and finerenone, we used RNA-sequencing on a human kidney cells HK-GFP-hMR. Our data provide the first complete transcriptome for aldosterone on a human renal cell line and support at the RNA level the benefit of finerenone for the treatment of kidney injury and fibrosis. Overall design: Human Kidney HK-GFP-hMR cells were treated 3 h with 1:1000 ethanol (Vehicle, Veh), 10 nM aldosterone (Aldo), 1 µM spironolactone (Spiro), 1 µM finerenone (Fine), or a combinaison of the molecules (Aldo + Spiro, Aldo + Fine).